Report: The Anti-Migraine Market 2007-2022 TOC

4.1 SWOT Analysis of the Anti-Migraine Market
- 4.1.1 Market Drivers
- 4.1.2 Market Restraints
- 4.1.3 Why Growth in the Market is Expected?
4.2 Success of the Triptan Drugs
- 4.2.1 Niche Markets and the Success of the Triptan
- 4.2.2 What are the Therapeutic Advantages Offered by the Newer Triptans?
- 4.2.3 Will a Single Triptan Reign Supreme?
4.3 Lack of Adequate Reimbursement Limits Potential of Anti-Migraine Drugs
4.4 Choosing the Right Medication
4.5 Patient Problems with Anti-Migraine drugs
4.6 What are the Costs of Migraine to the US?
- 4.6.1 Cost of Migraine
- 4.6.2 How much Does Migraine Cost the US in Terms of Medical, Missed Workdays and Lost Productivity?
4.7 FDA Reject Endo' s Attempt to Expand the Label for Frova
4.8 Complications of the Triptans

5.1 What is the Global Prevalence of Migraine?
- 5.1.1 Why Will the Prevalence of Migraine Increase?
5.2 Prevalence of Migraine in the US
5.3 What are the Affects of Migraine on Specific Populations?
- 5.3.1 Prevalence by Gender
  - 5.3.1.1 Menstrual Migraine
  - 5.3.1.2 Pregnancy and Migraine
- 5.3.2 Prevalence by Age
  - 5.3.2.1 Migraine in Children
  - 5.3.2.2 Migraine in Later Life

6.1 Agents in Phase II of Clinical Development
- 6.1.1 Addex' s ADX10059
- 6.1.2 GSK' s 274150, 468816 and 705498
6.2 Agents in Phase III of Clinical Development
- 6.2.1 Merck' s MK0974
- 6.2.2 GSK' s 406381
6.3 Time is Running out for Pozen & GSK After the FDA Request More Clinical Data on Trexima
6.4 Pozen' s MT-100
6.5 Discussion of Current Pipeline Developments
6.6 Summary of Pipeline Products Phase II and Above

8.1 Migraine is a Serious Condition with High Prevalence
8.2 Migraine Market Analysis
- 8.2.1 The Anti-Migraine Market Will Suffer From the Patent Expiry of its Leading Product
- 8.2.2 How have Anti-Migraine Drugs Succeeded?
- 8.2.3 How an Increase in Prevalence will affect Sales Growth
- 8.2.4 Why is a Growth in the Market Expected?
- 8.2.5 Niche Markets - Menstrual Migraine
- 8.2.6 Market Drivers
- 8.2.7 Market Restraints
8.3 Geographical Breakdown of Revenues in the Anti-Migraine Market
- 8.3.1 Sales of Anti-Migraine Drugs Will Decrease in the US from 2007 to 2012
- 8.3.2 France Will Have the Second-Highest Sales of Anti-Migraine Drugs
8.4 There are Promising Developments Currently in Mid to Late Stage Clinical Testing
8.5 Outlook for the Future of the Anti-Migraine Market

Table 2.1 FDA Approved Triptans for Migraine Treatment
Table 2.2 FDA Approved Ergots for Migraine Treatment
Table 2.3 FDA Approved Analgesics for Migraine Treatment
Table 2.4 FDA Approved NSAIDs for Migraine Treatment
Table 3.1 The World Anti-Migraine Market Forecast ($m), 2007-2022
Table 3.2 Imitrex Forecast ($m), 2007-2012
Table 3.3 Zomig Forecast ($m), 2007-2012
Table 3.4 Relpax Forecast ($m), 2007-2012
Table 3.5 Top 10 Leading Companies in the Anti-Migraine Market, Revenue and Market Share, 2006
Table 3.6 Top Ten Countries in the Anti-Migraine Market Revenue ($m) Forecast 2007-2012
Table 4.1 SWOT Analysis of the Anti-Migraine Market
Table 4.2 Economic Burden of Migraine in the US
Table 5.1 Lifetime Prevalence of Headaches among Gender
Table 6.1 Summary of Pipeline Products Phase II and Above, 2007
Table 8.1 Geographical Breakdown of Revenues in the Anti-Migraine Market ($m), 2006-2012

Companies Mentioned in this Report

The Anti-Migraine Market 2007-2022